Cargando…

Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain

OBJECTIVE: Observations in real-world settings support and extend findings demonstrated in randomized controlled trials that show flash glucose monitoring improves glycemic control. In this study, Spain-specific relationships between testing frequency and glycemic parameters were investigated under...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez-Peralta, Fernando, Dunn, Timothy, Landuyt, Katherine, Xu, Yongjin, Merino-Torres, Juan Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103828/
https://www.ncbi.nlm.nih.gov/pubmed/32198165
http://dx.doi.org/10.1136/bmjdrc-2019-001052
_version_ 1783512120855363584
author Gomez-Peralta, Fernando
Dunn, Timothy
Landuyt, Katherine
Xu, Yongjin
Merino-Torres, Juan Francisco
author_facet Gomez-Peralta, Fernando
Dunn, Timothy
Landuyt, Katherine
Xu, Yongjin
Merino-Torres, Juan Francisco
author_sort Gomez-Peralta, Fernando
collection PubMed
description OBJECTIVE: Observations in real-world settings support and extend findings demonstrated in randomized controlled trials that show flash glucose monitoring improves glycemic control. In this study, Spain-specific relationships between testing frequency and glycemic parameters were investigated under real-world settings. RESEARCH DESIGN AND METHODS: Deidentified glucose and user scanning data were analyzed and readers were rank ordered into 20 equal sized groups by daily scan frequency. Glucose parameters were calculated for each group: estimated HbA1c, time below range (<70 and ≤54 mg/dL), within range (70–180 mg/dL), and above range (>180 mg/dL). Glycemic variability (GV) metrics were described and data obtained from sensors in Spain and worldwide were compared. RESULTS: Spanish users (n=22 949) collected 37.1 million glucose scans, 250 million automatically recorded glucose readings, and checked glucose values via a mean of 13 scans/day. Estimated HbA1c, time below 70 mg/dL, at or below 54 mg/dL, above 180 mg/dL, and GV metrics were significantly lower in the highest compared with lowest scan rate group (39.6 to 3.9 scans/day). Time-in-range was higher for the highest versus lowest scan rate group at 15.6 vs 11.5 hours/day, respectively. GV metrics correlated positively with time below 70 mg/dL, at or below 54 mg/dL, above 180 mg/dL, and negatively with time-in-range. The relationship between glucose metrics and scan rate was similar in Spain and worldwide. However, time in hypoglycemia in Spain was higher in the groups with lower scan rates. CONCLUSIONS: As seen in clinical trials, flash glucose monitoring in real-world settings allows frequent glucose checks. High scan rates are associated with the favorable glycemic markers of increased time-in-range and reduced time in hyperglycemia and hypoglycemia, and GV. The same trends, with unique nuances, are observed in both Spanish and global data.
format Online
Article
Text
id pubmed-7103828
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-71038282020-03-31 Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain Gomez-Peralta, Fernando Dunn, Timothy Landuyt, Katherine Xu, Yongjin Merino-Torres, Juan Francisco BMJ Open Diabetes Res Care Emerging Technologies, Pharmacology and Therapeutics OBJECTIVE: Observations in real-world settings support and extend findings demonstrated in randomized controlled trials that show flash glucose monitoring improves glycemic control. In this study, Spain-specific relationships between testing frequency and glycemic parameters were investigated under real-world settings. RESEARCH DESIGN AND METHODS: Deidentified glucose and user scanning data were analyzed and readers were rank ordered into 20 equal sized groups by daily scan frequency. Glucose parameters were calculated for each group: estimated HbA1c, time below range (<70 and ≤54 mg/dL), within range (70–180 mg/dL), and above range (>180 mg/dL). Glycemic variability (GV) metrics were described and data obtained from sensors in Spain and worldwide were compared. RESULTS: Spanish users (n=22 949) collected 37.1 million glucose scans, 250 million automatically recorded glucose readings, and checked glucose values via a mean of 13 scans/day. Estimated HbA1c, time below 70 mg/dL, at or below 54 mg/dL, above 180 mg/dL, and GV metrics were significantly lower in the highest compared with lowest scan rate group (39.6 to 3.9 scans/day). Time-in-range was higher for the highest versus lowest scan rate group at 15.6 vs 11.5 hours/day, respectively. GV metrics correlated positively with time below 70 mg/dL, at or below 54 mg/dL, above 180 mg/dL, and negatively with time-in-range. The relationship between glucose metrics and scan rate was similar in Spain and worldwide. However, time in hypoglycemia in Spain was higher in the groups with lower scan rates. CONCLUSIONS: As seen in clinical trials, flash glucose monitoring in real-world settings allows frequent glucose checks. High scan rates are associated with the favorable glycemic markers of increased time-in-range and reduced time in hyperglycemia and hypoglycemia, and GV. The same trends, with unique nuances, are observed in both Spanish and global data. BMJ Publishing Group 2020-03-19 /pmc/articles/PMC7103828/ /pubmed/32198165 http://dx.doi.org/10.1136/bmjdrc-2019-001052 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Emerging Technologies, Pharmacology and Therapeutics
Gomez-Peralta, Fernando
Dunn, Timothy
Landuyt, Katherine
Xu, Yongjin
Merino-Torres, Juan Francisco
Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
title Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
title_full Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
title_fullStr Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
title_full_unstemmed Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
title_short Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain
title_sort flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from spain
topic Emerging Technologies, Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103828/
https://www.ncbi.nlm.nih.gov/pubmed/32198165
http://dx.doi.org/10.1136/bmjdrc-2019-001052
work_keys_str_mv AT gomezperaltafernando flashglucosemonitoringreducesglycemicvariabilityandhypoglycemiarealworlddatafromspain
AT dunntimothy flashglucosemonitoringreducesglycemicvariabilityandhypoglycemiarealworlddatafromspain
AT landuytkatherine flashglucosemonitoringreducesglycemicvariabilityandhypoglycemiarealworlddatafromspain
AT xuyongjin flashglucosemonitoringreducesglycemicvariabilityandhypoglycemiarealworlddatafromspain
AT merinotorresjuanfrancisco flashglucosemonitoringreducesglycemicvariabilityandhypoglycemiarealworlddatafromspain